糖酵解
单核细胞
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒学
2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
医学
生物
免疫学
新陈代谢
内科学
疾病
传染病(医学专业)
爆发
作者
Ana Campos Codo,Gustavo Gastão Davanzo,Lauar de Brito Monteiro,Gabriela Fabiano de Souza,Stéfanie Primon Muraro,João Victor Virgílio-da-Silva,Juliana Silveira Prodonoff,Victor Corasolla Carregari,Carlos Alberto Oliveira de Biagi,Fernanda Crunfli,Jeffersson Leandro Jimenez Restrepo,Pedro Henrique Vendramini,Guilherme Reis‐de‐Oliveira,Karina Bispo-dos-Santos,Daniel A. Toledo-Teixeira,Pierina Lorencini Parise,Matheus Cavalheiro Martini,Rafael Elias Marques,Helison Rafael Pereira do Carmo,Alexandre Borin
出处
期刊:Cell Metabolism
[Cell Press]
日期:2020-07-17
卷期号:32 (3): 437-446.e5
被引量:776
标识
DOI:10.1016/j.cmet.2020.07.007
摘要
COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals with uncontrolled glucose levels are more prone to develop the severe form of COVID-19. The molecular mechanism underlying SARS-CoV-2 infection and what determines the onset of the cytokine storm found in severe COVID-19 patients are unknown. Monocytes and macrophages are the most enriched immune cell types in the lungs of COVID-19 patients and appear to have a central role in the pathogenicity of the disease. These cells adapt their metabolism upon infection and become highly glycolytic, which facilitates SARS-CoV-2 replication. The infection triggers mitochondrial ROS production, which induces stabilization of hypoxia-inducible factor-1α (HIF-1α) and consequently promotes glycolysis. HIF-1α-induced changes in monocyte metabolism by SARS-CoV-2 infection directly inhibit T cell response and reduce epithelial cell survival. Targeting HIF-1ɑ may have great therapeutic potential for the development of novel drugs to treat COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI